Physician profile
Patrick David Ginn
NPI 1790799864
$7,005.91
in general payments reported to CMS, 2019-2025
32 companies · $731 in 2025
The $731 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,175 · 2020: $731 · 2021: $550 · 2022: $1,765 · 2023: $1,322 · 2024: $732 · 2025: $731.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,766 · Education: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,765.81 |
| Education | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,151.41 | 2019-2025 | |
| Gilead Sciences, INC. | $1,095.45 | 2019-2023 | Vemlidy, Epclusa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $638.98 | 2019-2025 | Xifaxan |
| Janssen Biotech, INC. | $580.19 | 2019-2025 | Stelara, Tremfya |
| Celgene Corporation | $354.48 | 2021-2024 | Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $288.82 | 2019-2024 | Entyvio |
| Madrigal Pharmaceuticals | $266.80 | 2024-2025 | Rezdiffra, Resmetirom |
| E.R. Squibb & Sons, L.L.C. | $219.05 | 2021-2022 | |
| Intercept Pharmaceuticals, INC. | $203.86 | 2020-2024 | Ocaliva |
| Qol Medical, LLC | $138.64 | 2022-2024 | Sucraid, Sucraid |
| Ardelyx, INC. | $131.92 | 2022-2025 | Ibsrela |
| Merck Sharp & Dohme LLC | $121.76 | 2019-2022 | |
| Pfizer INC. | $112.21 | 2019-2025 | |
| Janssen Scientific Affairs, LLC | $95.58 | 2022 | |
| Lilly USA, LLC | $74.11 | 2024 | Omvoh |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Covidien Lp | $69.24 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $62.55 | 2025 | Iqirvo |
| Genzyme Corporation | $50.64 | 2023-2025 | |
| Nestle Healthcare Nutrition INC. | $39.70 | 2022-2023 | |
| Allergan, INC. | $39.13 | 2019 | |
| Braintree Laboratories, INC. | $38.28 | 2020-2023 | Sutab |
| Daiichi Sankyo INC. | $36.53 | 2019-2022 | |
| Ironwood Pharmaceuticals, INC | $29.49 | 2019-2020 | |
| Medtronic, INC. | $27.02 | 2024 | Synchromedii |
| Vivus LLC | $24.17 | 2022 | |
| Novo Nordisk INC | $22.71 | 2025 | Wegovy |
| Celltrion USA INC. | $19.82 | 2024 | Vegzelma |
| Shionogi INC | $16.92 | 2019 | |
| Redhill Biopharma INC. | $16.84 | 2020 | |
| Phathom Pharmaceuticals, INC. | $14.55 | 2025 | Voquezna |
| Ferring Pharmaceuticals INC. | $13.87 | 2022 | |
| Micro-Tech Endoscopy USA, INC. | $11.19 | 2023 | Lockado |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Ginn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.